29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The blood-brain barrier (BBB) is a vital boundary between neural tissue and circulating blood. The BBB's unique and protective features control brain homeostasis as well as ion and molecule movement. Failure in maintaining any of these components results in the breakdown of this specialized multicellular structure and consequently promotes neuroinflammation and neurodegeneration. In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged and more permeable BBB can pose serious challenges to drug delivery into the brain. The use of nanoparticle (NP) formulations able to encapsulate molecules with therapeutic value, while targeting specific transport processes in the brain vasculature, may enhance drug transport through the BBB in neurodegenerative/ischemic disorders and target relevant regions in the brain for regenerative processes. In this review, we will discuss BBB composition and characteristics and how these features are altered in pathology, namely in stroke, AD and PD. Additionally, factors influencing an efficient intravenous delivery of polymeric and inorganic NPs into the brain as well as NP-related delivery systems with the most promising functional outcomes will also be discussed.

          Related collections

          Author and article information

          Journal
          J Control Release
          Journal of controlled release : official journal of the Controlled Release Society
          Elsevier BV
          1873-4995
          0168-3659
          Aug 10 2016
          : 235
          Affiliations
          [1 ] Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal.
          [2 ] Biocant - Center of Innovation in Biotechnology, 3060-197 Cantanhede, Portugal; Programme in Experimental Biology and Biomedicine (PDBEB), Center for Neuroscience and Cell Biology, 3004-504 Coimbra, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal; Science Faculty Jean Perrin, University of Artois, Lens, France.
          [3 ] Biocant - Center of Innovation in Biotechnology, 3060-197 Cantanhede, Portugal; Institute for Interdisciplinary Research, University of Coimbra (IIIUC), 3030-789 Coimbra, Portugal; CNC - Center for Neuroscience and Cell Biology, 3004-504 Coimbra, Portugal. Electronic address: lino@biocant.pt.
          [4 ] Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal. Electronic address: libernardino@gmail.com.
          Article
          S0168-3659(16)30323-6
          10.1016/j.jconrel.2016.05.044
          27208862
          89986425-1b7a-40b4-ad01-a3725d43a0a6
          History

          Alzheimer's disease,Blood–brain barrier,Brain repair,Nanoparticles,Parkinson's disease,Stroke

          Comments

          Comment on this article